Notably, simvastatin has been shown to suppress PKM2-dependent glycolysis by targeting the HIF-1α/PPAR-γ/PKM2 axis, thereby inhibiting tumor cell proliferation, promoting apoptosis, and sensitizing HCC cells to sorafenib treatment [27]. This evidence concerns the gene HIF1A and hepatocellular carcinoma.